Welzel et al. [52] have analyzed the relationship between variants in the IFN-α pathway and SVR among participants in the hepatitis C antiviral long-term treatment against the cirrhosis (HALT-C) trial. The gene discussed is IFNA1; the disease is Cirrhosis.